Summit Therapeutics shares fall over 3% post 3Q earnings, ivonescimab plan advances
NegativeFinancial Markets

Summit Therapeutics saw its shares drop over 3% following the release of its third-quarter earnings report. Despite the decline in stock value, the company is making progress with its ivonescimab plan, which is crucial for its future growth. Investors are closely watching how these developments will impact the company's trajectory, especially in a competitive market.
— Curated by the World Pulse Now AI Editorial System